# Effects of Proton Therapy on Cardiac Fibrosis, Calcium Homeostasis, and AQP4 Expression in Hypergravity-Exposed Rats

**Authors:** Hyewon Park, Bokyeong Park, Kyu-Sung Kim, Hyelim Park, Junbeom Park

PMC · DOI: 10.3390/ijms26136326 · International Journal of Molecular Sciences · 2025-06-30

## TL;DR

Proton therapy may protect the heart from damage caused by hypergravity, as seen in rats.

## Contribution

This study is the first to show that proton therapy can mitigate hypergravity-induced cardiac fibrosis and calcium imbalance.

## Key findings

- Hypergravity increased cardiac fibrosis markers like TGF-β1, MMP9, and MMP2 in rats.
- Proton therapy reduced fibrosis markers and improved calcium homeostasis in hypergravity-exposed rats.
- AQP4 expression was also affected in rats exposed to hypergravity and proton therapy.

## Abstract

Proton therapy is increasingly used to treat pediatric and adult brain tumors, but there is still uncertainty surrounding the biological effects of protons on the heart. Also, the molecular and functional responses to proton irradiation are still unknown. This study investigates the effect of protons on cardiac disease by comparing their effects on the hearts of rats exposed to hypergravity. A total of 20 Sprague Dawley rats were tested, including a group that was irradiated with 0.1 Gy of protons to the heart, a group exposed to hypergravity, a group exposed to both protons and hypergravity, and a control group. Changes in AQP4, calcium homeostasis, and fibrosis-related markers were investigated using Western blotting, immunohistochemistry, etc. The proton-irradiated group showed no changes compared to the control group. In rats exposed to hypergravity, the cardiac fibrosis markers TGF-ꞵ1, MMP9, and MMP2 were increased. On the other hand, the group exposed to hypergravity followed by proton irradiation tended to display a significant decrease in these markers. Along with reduced fibrosis-related markers, the consistent tendency was also confirmed in the cardiac calcium homeostasis-related proteins and AQP4 through Western blotting. In summary, our findings indicate that rats subjected to hypergravity experienced both cardiac hypertrophy and fibrosis, while proton therapy appeared to mitigate the effects of cardiac disease. These results suggest that proton therapy prevents heart disease triggered by hypergravity, providing insights for protecting astronauts’ cardiovascular health.

## Linked entities

- **Genes:** TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040], MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318], MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313], AQP4 (aquaporin 4) [NCBI Gene 361]

## Full-text entities

- **Genes:** Mmp2 (matrix metallopeptidase 2) [NCBI Gene 81686], Aqp4 (aquaporin 4) [NCBI Gene 25293] {aka AQP-4, Miwc, WCH4}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 81687]
- **Diseases:** brain tumors (MESH:D001932), cardiac disease (MESH:D006331), Cardiac Fibrosis (MESH:D005355), cardiac hypertrophy (MESH:D006332)
- **Chemicals:** Calcium (MESH:D002118)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12250340/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12250340/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12250340/full.md

---
Source: https://tomesphere.com/paper/PMC12250340